Brokerages Anticipate Bellerophon Therapeutics Inc (BLPH) to Announce -$0.24 Earnings Per Share

Brokerages predict that Bellerophon Therapeutics Inc (NASDAQ:BLPH) will announce earnings of ($0.24) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Bellerophon Therapeutics’ earnings. Bellerophon Therapeutics posted earnings per share of ($0.35) in the same quarter last year, which suggests a positive year over year growth rate of 31.4%. The business is expected to announce its next quarterly earnings results on Monday, March 12th.

On average, analysts expect that Bellerophon Therapeutics will report full-year earnings of ($1.18) per share for the current financial year. For the next fiscal year, analysts anticipate that the company will post earnings of ($0.98) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Bellerophon Therapeutics.

Bellerophon Therapeutics (NASDAQ:BLPH) last released its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.22) earnings per share for the quarter, hitting the consensus estimate of ($0.22).

Several institutional investors have recently added to or reduced their stakes in the company. VHCP Management II LLC acquired a new position in shares of Bellerophon Therapeutics during the 3rd quarter worth about $4,720,000. Susquehanna International Group LLP acquired a new position in shares of Bellerophon Therapeutics during the 2nd quarter worth about $1,316,000. Finally, Vanguard Group Inc. grew its stake in Bellerophon Therapeutics by 52.6% in the 2nd quarter. Vanguard Group Inc. now owns 612,641 shares of the biotechnology company’s stock valued at $821,000 after buying an additional 211,111 shares during the last quarter. Institutional investors own 43.51% of the company’s stock.

Bellerophon Therapeutics (NASDAQ BLPH) opened at $2.18 on Friday. The firm has a market cap of $77.06 and a PE ratio of -1.68. Bellerophon Therapeutics has a 52 week low of $0.61 and a 52 week high of $2.74.

COPYRIGHT VIOLATION WARNING: This news story was first published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.

Get a free copy of the Zacks research report on Bellerophon Therapeutics (BLPH)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Bellerophon Therapeutics (NASDAQ:BLPH)

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply